CS
NGNE icon

Credit Suisse’s Neurogene NGNE Stock Holding History

Credit Suisse’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 4073
2022
Q3 		$0 Sell
1
-1
-50% -$20 ﹤0.01% 4191
2022
Q2 		$0 Buy
+2
New +$49 ﹤0.01% 4174
2021
Q4 		– Sell
-886
Closed -$128K – 4618
2021
Q3 		$128K Sell
886
-3
-0.3% -$459 ﹤0.01% 4298
2021
Q2 		$163K Buy
889
+8
+0.9% +$1.77K ﹤0.01% 4311
2021
Q1 		$216K Sell
881
-1,227
-58% -$314K ﹤0.01% 4101
2020
Q4 		$594K Buy
2,108
+1,378
+189% +$337K ﹤0.01% 3700
2020
Q3 		$175K Buy
+730
New +$177K ﹤0.01% 3861
2016
Q4 		– Sell
-2,694
Closed -$719K – 4183
2016
Q3 		$719K Buy
2,694
+1,539
+133% +$310K ﹤0.01% 3213
2016
Q2 		$154K Buy
1,155
+305
+36% +$48.5K ﹤0.01% 3957
2016
Q1 		$149K Buy
850
+93
+12% +$18.1K ﹤0.01% 3756
2015
Q4 		$188K Buy
+757
New +$199K ﹤0.01% 3915

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Credit Suisse's NGNE Position: Q4 2022 in Review

Credit Suisse sold out of Neurogene (NGNE) in Q4 2022, closing a stake of 1 share.

Credit Suisse first reported a position in NGNE in Q4 2015 and held it in 11 quarters. The position peaked at $719K in Q3 2016. 45 funds tracked by Wall St. Rank hold NGNE as of Q4 2022.

  • Credit Suisse reported no remaining Neurogene position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Neurogene share in Q4 2022.
  • Credit Suisse first reported a position in Neurogene in Q4 2015 and held it in 11 quarters.
  • Credit Suisse's Neurogene position peaked at $719K in Q3 2016.
  • 45 funds tracked by Wall St. Rank held Neurogene as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.